LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

Nephros Fourth Quarter and Fiscal Year 2022 Financial Results Conference Call

February 22, 2023 | Last Trade: US$1.49 0.005 0.34

SOUTH ORANGE, NJ, Feb. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced it will file its fourth quarter and fiscal 2022 results on Wednesday, March 8, 2023 after market close and will host a conference call that same day at 4:30pm ET.

Participants may dial into the call as follows:
Domestic access: 1 (844) 808-7106
International access: 1 (412) 317-5285

Upon joining, please ask to be joined into the Nephros conference call.

An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.

Alternatively, a replay of the call may be accessed until March 15th, 2023 at 1 (877) 344-7529 or 1 (412) 317-0088 for international callers and entering replay access code: 9907282.

About Nephros
Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within the healthcare and commercial markets, offering both proactive and emergency solutions for water management. 

For more information about Nephros, please visit us at nephros.com.

Investor Relations Contacts:
Kirin Smith, President
PCG Advisory, Inc.
(646) 823-8656
This email address is being protected from spambots. You need JavaScript enabled to view it. 


Andy Astor, CEO
Nephros, Inc.
(201) 343-5202 x120
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB